Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Arcutis Biotherapeutics, Inc. (ARQT) has a Wall Street consensus price target of $33.33, based on estimates from 12 covering analysts. With the stock currently trading at $26.97, this represents a potential upside of +23.6%. The company has a market capitalization of $3.33B.
Analyst price targets range from a low of $29.00 to a high of $37.00, representing a 24% spread in expectations. The median target of $34.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ARQT trades at a trailing P/E of -207.5x and forward P/E of 73.5x. Analysts expect EPS to grow +408.5% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ARQT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for ARQT is $33.33, representing 23.6% upside from the current price of $26.97. With 12 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ARQT has a consensus rating of "Buy" based on 12 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $33.33 implies 23.6% upside from current levels.
At a forward P/E of 73.4677x, ARQT trades at a premium valuation. The consensus price target of $33.33 (23.6% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $37 for ARQT, while the most conservative target is $29. The consensus of $33.33 represents the median expectation. These targets typically reflect 12-month expectations.
ARQT is moderately covered, with 12 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ARQT stock forecast based on 12 Wall Street analysts shows a consensus price target of $33.33, with estimates ranging from $29 (bear case) to $37 (bull case). The median consensus rating is "Buy".
ARQT trades at a forward P/E ratio of 73.5x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on ARQT, with a "Buy" consensus rating and $33.33 price target (23.6% upside). 10 of 12 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ARQT analyst price targets range from $29 to $37, a 24% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $33.33 consensus represents the middle ground.